Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Abeprazan (DWP14012) is a potassium-competitive acid blocker and it is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Abeprazan (DWP14012) is a potassium-competitive acid blocker and it is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. |
In vitro | The mechanism of action of Abeprazan is reversibly binding to H+, K+‐ATPase. It unlike that of PPIs, does not require acidic environment for drug activation[1]. |
In vivo | In various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1], DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB. |
Synonyms | DWP14012 |
Molecular Weight | 410.41 |
Formula | C19H17F3N2O3S |
CAS No. | 1902954-60-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Abeprazan 1902954-60-2 Others DWP-14012 DWP 14012 DWP14012 inhibitor inhibit